Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Sasya Dronavalli's research focuses on the clinical outcomes and risk factors associated with cytomegalovirus (CMV) reactivation in patients undergoing treatment for multiple myeloma. This includes investigating CMV reactivation in patients treated with teclistamab, a bispecific antibody, examining both clinical outcomes and identified risk factors. Dronavalli's work also addresses disseminated Bartonella henselae infection in patients with relapsed or refractory multiple myeloma following autologous stem cell transplantation. Dronavalli has 8 total publications and collaborates with researchers at the University of Arkansas for Medical Sciences, including Syed Naqvi and Fenghuang Zhan.
Metrics
- Publications: 9
Selected Publications
-
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)
-
Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)
-
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
-
Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation (2025)
Collaboration Network
Top Collaborators
- Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation
- Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell Transplantation
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Similar Researchers
Based on overlapping research topics